Apr 7, 2017
I have purposely used the terms interventional orthopedics and cellular orthopedics when referring to regenerative medicine to remind my reader that I am an orthopedic surgeon. Later in life, I graduated into my present role as a clinician seeking to assist a patient in postponing, at times avoiding a major surgical procedure for an arthritic or otherwise compromised joint. You will note that I limit my discussion and topic matter to the musculoskeletal system and, do not allow vanity or greed to suggest that I am willing to expand my scope of care directed to conditions and diseases for which I am willing to provide treatment. In my 37-year commitment to reconstructive orthopedics and joint replacement surgery, I did not increase my scope of services outside the musculoskeletal system and I won’t consider anything more in my regenerative medicine undertakings, today.
To take things a bit further, when it comes to cartilage damage in any joint and from any causation, there are three categories of care: Palliative, Reparative and Restorative. In the first category, palliative, I do offer anti-inflammatory prescription, cortisone injection and hyaluronic intervention. At times, for those who meet inclusion criteria, I even enroll patients in an amniotic fluid clinical trial for pain management when deemed appropriate knowing there is no regenerative or even reparative potential therein. Reparative may take place during a Bone Marrow Concentrate procedure; but my goal is Restorative (Regeneration). The only FDA complaint method for delivering stem cells to an arthritic joint is the use of your aspirated and then concentrated bone marrow from your pelvis. In spite of the misleading and false news to be found on the various web sites, in order for stem cells to be separated from fat, an enzymatic digestion must take place and that manipulation renders adipose derived stem cell usage contrary to FDA mandates. Furthermore, there is no published scientific literature demonstrating adipose derived stem cells are of value in the care and treatment of an arthritic or otherwise altered joint function.
When you decide to seek out a provider of regenerative services, a very important part of the decision- making process should be to question that provider as to whether services are limited to the musculoskeletal system and what outcomes and data of that particular practice experiences? I have noted recently that my data and outcomes are being posted on web sites around the country as if the results were being achieved in settings other than mine.
If you want to learn more about postponing or perhaps even avoiding surgery for a joint that alters your quality of life, call 312-475-1893.
To learn more, check out my web site at www.Sheinkopmd.com
View my webinar at www.ilcellulartherapy.com
Tags: arthritis, Bone Marrow Concentrate, Clinical Trial. Mitchell B. Sheinkop, Concentrated Stem Cell Plasma, Interventional Orthopedics, joint pain, joint replacement, Knee, knee pain, regenerative medicine, stem cells
Mar 27, 2017
I am an orthopedic surgeon. The new focus for the arthritic joint is restoration and not replacement. Almost five years ago, I joined that emerging initiative after a 37-year professional career of having replaced joints. One of the recent problems emerging in this discipline of regenerative medicine is that marketing is inaccurate. There is no quick fix be it a replacement or an interventional orthopedic procedure. What stem cells do not risk is a joint replacement failure requiring a repeat procedure (revision), a significant occurrence of infection, a blood clot or a nerve injury. As a surgeon, I replaced arthritic joints because the original cartilage had degenerated and the bone surfaces degraded. My effort now is to restore and not replace. This is an evolving field using stem cells derived from bone marrow, using inflammatory blockers, and growth factors.
Finding a good interventional cellular orthopedist is partly a numbers game. Research shows a regenerative specialist must do a minimum of 50 interventions a year to provide a consistently satisfactory end result. Five years ago, the orthopedic surgical community including my past associates were all nay-sayers. Today, they are embracing that which I pioneered. While there are of this time, no true standards and regulatory bodies outside the FDA, in my office, I have pioneered a standardization initiative via qualitative analysis of that which we aspirate and then inject. The meeting of the American Academy of Orthopedic Surgeons in San Diego ending last week dedicated a relatively large part of the educational and scientific agenda to regenerative medicine and interventional orthopedics. All this being said, the patient seeking out one of America’s fastest growing procedures must assure the provider is experienced, knowledgeable and be prepared to meet a patient’s expectations. The explosive growth of those holding themselves out to be capable of delivery an excellent or at least a good regenerative outcome is not supported by evidence or experience. To repeat what I indicated above, all doctors are not the same. If you want the evidence, make an appointment. If you want a procedure by those who market themselves as treating Alzheimer’s, Alopecia, facial wrinkles, Arthritis, so on and so forth all under the same roof, I am not the that clinician.
To learn more, check out my web site at www.Sheinkopmd.com
View my webinar at www.ilcellulartherapy.com
Or call for an appointment 847 390 7666
Tags: arthritis, bone marrow, Clinical Trial. Mitchell B. Sheinkop, Concentrated Stem Cell Plasma, Interventional Orthopedics, Mesenchymal Stem Cell, Regenerative, regenerative medicine, stem cell treatment
Feb 28, 2017
When it comes to cellular orthopedics, for me, it is a matter of honor and self-interest.
If you aren’t aware of the bogus stem cell claims or “false news”, read the LA Times article that appeared last week http://www.latimes.com/business/hiltzik/la-fi-hiltzik–oz-stem-cell-20170213-story.html
The article followed a Dr. Oz television expose where he focused on charlatans victimizing the public with false information at extremely outrageous fee schedules. The egregious behavior stemmed (no pun intended) from mostly California based clinics but Texas was another state exposed. For those who read this Blog, you are familiar with the false advertising of “Stem Cell Clinics” highlighting regenerative medicine via Amniotic Fluid for arthritis in Illinois, that I have repeatedly taken to task. To repeat, while there may be living cells when amniotic fluid is harvested, following collection, processing, sterilizing, irradiating, freezing and fast thawing, there are no living or viable stem cells in the pat being offered as a regenerative alternative. Dr. Oz took his expose a lot further calling attention to false claims without medical evidence wherein the so called regenerative medicine clinics he exposed offer treatment for every and any affliction of the human body.
Since the innovations introduced by Regenexx 10 years or so ago, interventional orthopedics has become an evidence based approach to sports medicine related injuries and as an alternative to a major surgical reconstruction or replacement for an arthritic or chronically injured bone or joint. I am a member of the Regenexx network and, have continued to compile and contribute scientific evidence to support the Regenexx mission. Our menu of surgical alternatives is directed to afflictions of the musculoskeletal system.
A patient attempting to postpone or avoid a major orthopedic procedure for an arthritic joint and return to a relatively symptom free functional quality of life may find legitimate, well intentioned and evidence based regenerative medicine and interventional cellular orthopedic initiatives. I am proud to be one of those clinical settings
Next week, I will complete my interview with Dr Mitchell Sheinkop, part two-focusing on common athletic injuries amenable to cellular orthopedics and joint condition amenable to stem cell intervention.
To schedule an appointment call (312) 475-1893
To visit my web site go to www.sheinkopmd.com
To watch my webinar visit www.ilcellulartherapy.com
Tags: Bone Marrow Concentrate, Clinical Studies, Clinical Trial. Mitchell B. Sheinkop, Concentrated Stem Cell Plasma, Interventional Orthopedics, Mesenchymal Stem Cell, regenerative medicine, stem cell treatment
Jan 20, 2017
Last week, a patient who had enrolled in the initial Regenexx Stem Cell Clinical Trial for an arthritic knee visited the office for his five year follow up. He had never paid a nickel out of pocket other than obligatory office co-pays for the intervention. Five years after the administration of concentrated bone marrow, he shared his dissatisfaction with the five-year outcome indicating he had scheduled a total knee replacement because of the ” failure”. The same week, four years after another patient had undergone a bone marrow concentrate intervention for his arthritic hip on a fee for service basis, the patient thanked me for having assisted his return to an active lifestyle. With the return of some symptoms, he asked that I repeat the procedure and help him delay a total hip replacement for another four years, perhaps longer.
What is the benchmark of success when it comes to a cellular orthopedic intervention? On the one hand, five-year postponement and electing to undergo a joint replacement or four years of enabling an active lifestyle and then repeating the intervention. From the humanistic side, the unhappy patient always had a demand and a complaint when seen over the five years while the positive patient always had a smile and a thank you.
Over the several years since beginning my Interventional Orthopedic Practice, I have significantly improved the techniques and technology. In addition, over the last month, I have added the technology enabling customization of the injectate with the addition of the Hemoanalyzer to our algorithm. As in any outcomes analysis, there is the subjective component and the objective component. The ultimate determinant as I see it is the activity profile and scoring.
My Interventional Orthopedic practice is focused on protecting my patients from unproven treatments that may be harmful and unethical, financially exploiting the public; First No Harm. Witness the seductive newspaper ads placed by non-MDs offering stem cells for regeneration using amniotic fluid. I am compliant with federal regulations and the Principal Investigator in a national Amniotic Fluid Clinical Trial. From a scientific perspective, while amniotic fluid may be beneficial for six to 18 months, the proper dosage has yet to be determined and there are insignificant living stem cells in that which is being offered. Also, note that tissue-based stem cell products may not be administered in the absence of an FDA approved indications or approved research protocol.
My Regenerative Medicine, Interventional Orthopedic practice is evidence based and everything that I do is under IRB protocols; that is FDA oversite.
To learn more, you may schedule a consultation by calling 312 475 1896
View my website www.sheinkopmd.com
View my webinar at www.ilcellulartherapy.com
Tags: arthritis, Bone Marrow Concentrate, Clinical Trial. Mitchell B. Sheinkop, Concentrated Stem Cell Plasma, joint replacement, stem cells
Jan 6, 2017
In reviewing the plethora of proliferating Regenerative Medicine web sites, I found one with multiple points of service in metropolitan Chicago offering platelet rich plasma, fat graft, adipose derived stem cells and bone marrow derived stem cells in an office setting for the treatment of ALS, Alzheimer’s, Erectile Dysfunction, Alopecia, Autism, Cerebral Palsy, Aesthetic improvement and so on and more. There was no end to the promises advanced. At no time was there any evidence of success posted and absolutely no data.
For the first 37 years of my orthopedic practice, I collected outcomes data for every patient in whom I performed a hip or knee replacement. Prior to a surgical procedure, I provided the patient with meaningful outcomes data concerning success and length before a revision surgery might be required. That scientific documentation was scientifically published and used globally for informed consent by orthopedic surgeons around the world. Anticipating the future, actually the present if you live in Alabama, not only do I quantitate that which is injected into an arthritic joint, I am able to qualitate the injectate. I refer to Alabama because that State requires a physician to know exactly what is being injected into a patient when a she or he administers such or the physician is not complaint with that state’s law. With the incorporation of Abbott’s Ruby hemoanalyzer into my Cellular Orthopedic practice, I meet ethical, moral, legal and scientific guidelines and anticipate what I believe will shortly become an FDA compliance requirement. My practice is limited to that which has data to support my recommendations for a symptomatic, arthritic joint; while at the same time documenting the quality and quantity of the combination of Bone Marrow Concentrate, Growth Factors and Platelet Rich Plasma I am injecting.
There is the beginning of an initiative to comply with an anticipated more stringent oversite by the FDA concerning the developing subspecialty of Interventional Orthopedics and I am thrilled to be part of that small group. The FDA is a governmental agency responsible for the well-being, health and safety of the public. While likesome charlatans might get by in the short term, I am thrilled to be part of this initial group of responsible Board Certified Orthopedic Surgeons, Physiatrists and Pain Management specialists providing scientifically supported, FDA compliant, Cellular Orthopedic and Regenerative Medicine options in Sports Medicine and for management of an arthritic joint.
You may schedule an appointment by calling 312 475 1893
My Website is reached at www.Sheinkopmd.com
You may watch my webinar at www.ilcellulartherapy.com
Tags: Bone Marrow Concentrate, Clinical Trial. Mitchell B. Sheinkop, Concentrated Stem Cell Plasma, Knee Pain Relief, Platelet Rich Plasma, PRP, stem cells
